Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Source and Search Strategy
2.2. Study Selection and Data Extraction
2.3. The Outcomes and Definitions
2.3.1. Primary Outcome
2.3.2. Secondary Outcomes
- Secondary attack rate following vaccination and reduction in disease severity in terms of hospitalization and severe symptoms.
- Assess the primary outcomes across the different routes of vaccine administration: intramuscular (IM), intradermal (ID), and subcutaneous (SC) routes.
- Assess the primary outcomes with different numbers of received doses of vaccines: one dose, two doses, and three doses.
- Address the duration of immunological response following vaccination.
- Highlight the effect of different formulations on vaccine immunogenicity.
- Evaluate the cross-reactivity of different vaccines used to prevent other OPXVs from providing protection against mpox.
- (1)
- Vaccine safety: The assessment of mpox vaccine safety involves the reporting and monitoring of any local or systemic adverse events that occur within 7 days after vaccination or during other specified periods, depending on the specific vaccine being evaluated.
- (2)
- Vaccine immunogenicity: Immunogenicity refers to the ability of the mpox vaccine to stimulate an immune response in the individual who receives it. It measures the mpox vaccine’s effectiveness in generating an immune reaction, such as the production of antibodies or the activation of specific immune cells, to protect against the target disease.
- (3)
- Vaccine efficacy: Vaccine efficacy is a measure of how well the mpox vaccine prevents the incidence of the disease, typically under controlled and ideal conditions. It is determined through RCTs by comparing the incidence of the disease in a vaccinated group with that in a placebo-controlled group.
- (4)
- Vaccine effectiveness: Vaccine effectiveness refers to the performance of the mpox vaccine in real-world conditions, beyond the controlled environment of RCTs. It assesses how well the vaccine performs in preventing the target disease within the general population through observational studies and population-based analyses.
2.4. Assessment of the Study Quality
2.5. Vaccine Formulations
3. Results
3.1. Summary of the Included Studies
3.2. The Overall Mpox Vaccines Efficacy and Effectiveness
3.3. Immunogenicity
3.4. Safety and Adverse Events
3.5. Vaccine Efficacy and Effectiveness
3.6. Route of Administration Intradermal, Intramuscular, Subcutaneous
3.7. Number of Doses
3.7.1. Single Dose
3.7.2. One Dose versus Two Doses
3.7.3. Third Dose
3.8. Duration of Serological Response
3.9. Formulation
3.10. Cross-Reactivity
4. Discussion
4.1. Vaccine Efficacy Is Variable Based on the Vaccine Type
4.2. Efficacy and Effectiveness of Monkeypox Vaccines
4.3. Vaccine Safety
4.4. Limitations and Strengths
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- Oliveira, G.P.; Rodrigues, R.A.L.; Lima, M.T.; Drumond, B.P.; Abrahão, J.S. Poxvirus host range genes and virus–host spectrum: A critical review. Viruses 2017, 9, 331. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Mpox Outbreak. Available online: https://www.paho.org/en/mpox (accessed on 25 May 2023).
- World Health Organization. 2022–2023 Mpox (Monkeypox) Outbreak: Global Trends. 2023. Available online: https://worldhealthorg.shinyapps.io/mpx_global/ (accessed on 25 May 2023).
- World Health Organization. Fifth Meeting of the International Health Regulations (2005) (IHR) Emergency Committee on the Multi-Country Outbreak of Mpox (Monkeypox). 2023. Available online: https://www.who.int/news/item/11-05-2023-fifth-meeting-of-the-international-health-regulations-(2005)-(ihr)-emergency-committee-on-the-multi-country-outbreak-of-monkeypox-(mpox) (accessed on 25 May 2023).
- Chen, N.; Li, G.; Liszewski, M.K.; Atkinson, J.P.; Jahrling, P.B.; Feng, Z.; Schriewer, J.; Buck, C.; Wang, C.; Lefkowitz, E.J. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 2005, 340, 46–63. [Google Scholar] [CrossRef] [PubMed]
- Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Neglected Trop. Dis. 2022, 16, e0010141. [Google Scholar] [CrossRef]
- Ghazy, R.M.; Hammad, E.; Hall, M.A.; Mahboob, A.; Zeina, S.; Elbanna, E.H.; Fadl, N.; Abdelmoneim, S.A.; ElMakhzangy, R.; Hammad, H.M. How can imported monkeypox break the borders? A rapid systematic review. Comp. Immunol. Microbiol. Infect. Dis. 2022, 92, 101923. [Google Scholar] [CrossRef]
- World Health Organization. Multi-Country Monkeypox Outbreak in Non-Endemic Countries. 2022. Available online: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385 (accessed on 25 May 2023).
- Knipe, D.; Howley, P.; Griffin, D.; Lamb, R.; Martin, M.; Roizman, B.; Straus, S. Fields Virology, Volumes 1 and 2; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2013. [Google Scholar]
- Reynolds, M.G.; Yorita, K.L.; Kuehnert, M.J.; Davidson, W.B.; Huhn, G.D.; Holman, R.C.; Damon, I.K. Clinical manifestations of human monkeypox influenced by route of infection. J. Infect. Dis. 2006, 194, 773–780. [Google Scholar] [CrossRef] [PubMed]
- McCollum, A.M.; Damon, I.K. Human monkeypox. Clin. Infect. Dis. 2014, 58, 260–267. [Google Scholar] [CrossRef] [PubMed]
- Al Awaidy, S.; Khamis, F.; Sallam, M.; Ghazy, R.; Zaraket, H. Monkeypox Outbreak: More queries posed as cases globally soar. Sultan Qaboos Univ. Med. J 2022, 23, 1. [Google Scholar] [CrossRef]
- O’Shea, J.; Filardo, T.D.; Morris, S.B.; Weiser, J.; Petersen, B.; Brooks, J.T. Interim guidance for prevention and treatment of monkeypox in persons with HIV infection—United States, August 2022. Morb. Mortal. Wkly. Rep. 2022, 71, 1023. [Google Scholar] [CrossRef]
- Nguyen, P.-Y.; Ajisegiri, W.S.; Costantino, V.; Chughtai, A.A.; MacIntyre, C.R. Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017–2020. Emerg. Infect. Dis. 2021, 27, 1007. [Google Scholar] [CrossRef]
- Ahmed, S.K.; Dabou, E.A.; Abdelsamad, S.; Mohamed, M.G.; Chandran, D.; Chakraborty, S.; Emran, T.B.; Dhama, K. Monkeypox virus infection and myocarditis: A review of current evidence and possible pathogenesis. Narra J. 2023, 3, e104. [Google Scholar] [CrossRef]
- Beer, E.M.; Rao, V.B. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Neglected Trop. Dis. 2019, 13, e0007791. [Google Scholar] [CrossRef] [PubMed]
- Malik, S.; Ahmad, T.; Ahsan, O.; Muhammad, K.; Waheed, Y. Recent Developments in Mpox Prevention and Treatment Options. Vaccines 2023, 11, 500. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Vaccines and Immunization for Monkeypox: Interim Guidance, 14 June 2022; World Health Organization: Geneva, Switzerland, 2022. [Google Scholar]
- Ophinni, Y.; Frediansyah, A.; Sirinam, S.; Megawati, D.; Stoian, A.M.; Enitan, S.S.; Akele, R.Y.; Sah, R.; Pongpirul, K.; Abdeen, Z. Monkeypox: Immune response, vaccination and preventive efforts. Narra J. 2022, 2, e90. [Google Scholar] [CrossRef]
- Hammarlund, E.; Lewis, M.W.; Carter, S.V.; Amanna, I.; Hansen, S.G.; Strelow, L.I.; Wong, S.W.; Yoshihara, P.; Hanifin, J.M.; Slifka, M.K. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat. Med. 2005, 11, 1005–1011. [Google Scholar] [CrossRef] [PubMed]
- Kenner, J.; Cameron, F.; Empig, C.; Jobes, D.V.; Gurwith, M. LC16m8: An attenuated smallpox vaccine. Vaccine 2006, 24, 7009–7022. [Google Scholar] [CrossRef]
- Sah, R.; Humayun, M.; Baig, E.; Farooq, M.; Hussain, H.G.; Shahid, M.U.; Cheema, H.A.; Chandran, D.; Yatoo, M.I.; Sharma, A.K. FDA’s authorized “JYNNEOS” vaccine for counteracting monkeypox global public health emergency; An update–Correspondence. Int. J. Surg. 2022, 107, 106971. [Google Scholar] [CrossRef]
- Carlin, E.P.; Giller, N.; Katz, R. Estimating the size of the US population at risk of severe adverse events from replicating smallpox vaccine. Public Health Nurs. 2017, 34, 200–209. [Google Scholar] [CrossRef]
- Cassimatis, D.C.; Atwood, J.E.; Engler, R.M.; Linz, P.E.; Grabenstein, J.D.; Vernalis, M.N. Smallpox vaccination and myopericarditis: A clinical review. J. Am. Coll. Cardiol. 2004, 43, 1503–1510. [Google Scholar] [CrossRef]
- Hazra, A.; Rusie, L.; Hedberg, T.; Schneider, J.A. Human monkeypox virus infection in the immediate period after receiving modified vaccinia Ankara vaccine. JAMA 2022, 328, 2064–2067. [Google Scholar] [CrossRef]
- Overton, E.T.; Schmidt, D.; Vidojkovic, S.; Menius, E.; Nopora, K.; Maclennan, J.; Weidenthaler, H. A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults. Vaccine 2023, 41, 397–406. [Google Scholar] [CrossRef]
- Eckart, R.E.; Love, S.S.; Atwood, J.E.; Arness, M.K.; Cassimatis, D.C.; Campbell, C.L.; Boyd, S.Y.; Murphy, J.G.; Swerdlow, D.L.; Collins, L.C. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 2004, 44, 201–205. [Google Scholar] [CrossRef] [PubMed]
- Ghazy, R.M.; Yazbek, S.; Gebreal, A.; Hussein, M.; Addai, S.A.; Mensah, E.; Sarfo, M.; Kofi, A.; AL-Ahdal, T.; Eshun, G. Monkeypox Vaccine Acceptance among Ghanaians: A Call for Action. Vaccines 2023, 11, 240. [Google Scholar] [CrossRef] [PubMed]
- Ghazy, R.M.; Okeh, D.U.; Sallam, M.; Hussein, M.; Ismail, H.M.; Yazbek, S.; Mahboob, A.; Abd ElHafeez, S. Psychological Antecedents of Healthcare Workers towards Monkeypox Vaccination in Nigeria. Vaccines 2022, 10, 2151. [Google Scholar] [CrossRef] [PubMed]
- Abd ElHafeez, S.; Gebreal, A.; Khalil, M.A.; Youssef, N.; Sallam, M.; Elshabrawy, A.; Abdel-Rahman, S.; Mahboob, A.S.; Yazbek, S.; Elbanna, E.H.; et al. Assessing disparities in medical students’ knowledge and attitude about monkeypox: A cross-sectional study of 27 countries across three continents. Front. Public Health 2023, 11, 1192542. [Google Scholar] [CrossRef] [PubMed]
- Moskalewicz, A.; Oremus, M. No clear choice between Newcastle–Ottawa Scale and Appraisal Tool for Cross-Sectional Studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer. J. Clin. Epidemiol. 2020, 120, 94–103. [Google Scholar] [CrossRef] [PubMed]
- Sterne, J.A.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016, 355, i4919. [Google Scholar] [CrossRef] [PubMed]
- Hartling, L.; Ospina, M.; Liang, Y.; Dryden, D.M.; Hooton, N.; Seida, J.K.; Klassen, T.P. Risk of bias versus quality assessment of randomised controlled trials: Cross sectional study. BMJ 2009, 339, b4012. [Google Scholar] [CrossRef]
- Thornhill, J.P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L.B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M.S. Monkeypox virus infection in humans across 16 countries—April–June 2022. N. Engl. J. Med. 2022, 387, 679–691. [Google Scholar] [CrossRef]
- Ilchmann, H.; Samy, N.; Reichhardt, D.; Schmidt, D.; Powell, J.D.; Meyer, T.P.; Silbernagl, G.; Nichols, R.; Weidenthaler, H.; De Moerlooze, L. One-and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. J. Infect. Dis. 2023, 227, 1203–1213. [Google Scholar] [CrossRef]
- Huhn, G.D.; Bauer, A.M.; Yorita, K.; Graham, M.B.; Sejvar, J.; Likos, A.; Damon, I.K.; Reynolds, M.G.; Kuehnert, M.J. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin. Infect. Dis. 2005, 41, 1742–1751. [Google Scholar] [CrossRef]
- Karem, K.L.; Reynolds, M.; Hughes, C.; Braden, Z.; Nigam, P.; Crotty, S.; Glidewell, J.; Ahmed, R.; Amara, R.; Damon, I.K. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin. Vaccine Immunol. 2007, 14, 1318–1327. [Google Scholar] [CrossRef]
- Frey, S.E.; Newman, F.K.; Kennedy, J.S.; Sobek, V.; Ennis, F.A.; Hill, H.; Yan, L.K.; Chaplin, P.; Vollmar, J.; Chaitman, B.R. Clinical and immunologic responses to multiple doses of IMVAMUNE®(Modified Vaccinia Ankara) followed by Dryvax® challenge. Vaccine 2007, 25, 8562–8573. [Google Scholar] [CrossRef] [PubMed]
- Parrino, J.; McCurdy, L.H.; Larkin, B.D.; Gordon, I.J.; Rucker, S.E.; Enama, M.E.; Koup, R.A.; Roederer, M.; Bailer, R.T.; Moodie, Z. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine 2007, 25, 1513–1525. [Google Scholar] [CrossRef] [PubMed]
- Seaman, M.S.; Wilck, M.B.; Baden, L.R.; Walsh, S.R.; Grandpre, L.E.; Devoy, C.; Giri, A.; Noble, L.C.; Kleinjan, J.A.; Stevenson, K.E. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J. Infect. Dis. 2010, 201, 1353–1360. [Google Scholar] [CrossRef] [PubMed]
- Wilck, M.B.; Seaman, M.S.; Baden, L.R.; Walsh, S.R.; Grandpre, L.E.; Devoy, C.; Giri, A.; Kleinjan, J.A.; Noble, L.C.; Stevenson, K.E. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): Effect of dose and route of administration. J. Infect. Dis. 2010, 201, 1361–1370. [Google Scholar] [CrossRef] [PubMed]
- Kennedy, J.S.; Gurwith, M.; Dekker, C.L.; Frey, S.E.; Edwards, K.M.; Kenner, J.; Lock, M.; Empig, C.; Morikawa, S.; Saijo, M. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J. Infect. Dis. 2011, 204, 1395–1402. [Google Scholar] [CrossRef]
- Greenberg, R.N.; Overton, E.T.; Haas, D.W.; Frank, I.; Goldman, M.; von Krempelhuber, A.; Virgin, G.; Bädeker, N.; Vollmar, J.; Chaplin, P. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J. Infect. Dis. 2013, 207, 749–758. [Google Scholar] [CrossRef]
- Duffy, J. Safety Monitoring of JYNNEOS Vaccine during the 2022 Mpox Outbreak—United States, May 22–October 21, 2022. MMWR. Morb. Mortal. Wkly. Rep. 2022, 71, 1555. [Google Scholar] [CrossRef]
- Farrar, J.L. Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons—29 US Jurisdictions, May 22–September 3, 2022. MMWR. Morb. Mortal. Wkly. Rep. 2022, 71, 1610. [Google Scholar] [CrossRef]
- Payne, A.B. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons—43 US Jurisdictions, July 31–October 1, 2022. MMWR. Morb. Mortal. Wkly. Rep. 2022, 71, 1560. [Google Scholar] [CrossRef]
- Payne, A.B. Incidence of monkeypox among unvaccinated persons compared with persons receiving ≥1 JYNNEOS vaccine dose—32 US jurisdictions, July 31–September 3, 2022. MMWR. Morb. Mortal. Wkly. Rep. 2022, 71, 1278. [Google Scholar] [CrossRef] [PubMed]
- Deputy, N.P.; Deckert, J.; Chard, A.N.; Sandberg, N.; Moulia, D.L.; Barkley, E.; Dalton, A.F.; Sweet, C.; Cohn, A.C.; Little, D.R. Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. N. Engl. J. Med. 2023, 388, 2434–2443. [Google Scholar] [CrossRef] [PubMed]
- Sharff, K.A.; Tandy, T.K.; Lewis, P.F.; Johnson, E.S. Cardiac events following JYNNEOS vaccination for prevention of Mpox. Vaccine 2023, 41, 3410–3412. [Google Scholar] [CrossRef] [PubMed]
- Fine, P.; Jezek, Z.; Grab, B.; Dixon, H. The transmission potential of monkeypox virus in human populations. Int. J. Epidemiol. 1988, 17, 643–650. [Google Scholar] [CrossRef] [PubMed]
- Rimoin, A.W.; Mulembakani, P.M.; Johnston, S.C.; Lloyd Smith, J.O.; Kisalu, N.K.; Kinkela, T.L.; Blumberg, S.; Thomassen, H.A.; Pike, B.L.; Fair, J.N. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. USA 2010, 107, 16262–16267. [Google Scholar] [CrossRef]
- Jezek, Z.; Marennikova, S.; Mutumbo, M.; Nakano, J.; Paluku, K.; Szczeniowski, M. Human monkeypox: A study of 2510 contacts of 214 patients. J. Infect. Dis. 1986, 154, 551–555. [Google Scholar] [CrossRef]
- Priyamvada, L.; Carson, W.C.; Ortega, E.; Navarra, T.; Tran, S.; Smith, T.G.; Pukuta, E.; Muyamuna, E.; Kabamba, J.; Nguete, B.U. Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo. Vaccine 2022, 40, 7321–7327. [Google Scholar] [CrossRef]
- Arbel, R.; Sagy, Y.W.; Zucker, R.; Arieh, N.G.; Markovits, H.; Abu-Ahmad, W.; Battat, E.; Ramot, N.; Carmeli, G.; Mark-Amir, A. Effectiveness of a single-dose Modified Vaccinia Ankara in Human Monkeypox: An observational study. Res. Sq. 2022, 1–10. [Google Scholar] [CrossRef]
- Wolff Sagy, Y.; Zucker, R.; Hammerman, A.; Markovits, H.; Arieh, N.G.; Abu Ahmad, W.; Battat, E.; Ramot, N.; Carmeli, G.; Mark-Amir, A. Real-world effectiveness of a single dose of mpox vaccine in males. Nat. Med. 2023, 29, 748–752. [Google Scholar] [CrossRef]
- Zaeck, L.M.; Lamers, M.M.; Verstrepen, B.E.; Bestebroer, T.M.; van Royen, M.E.; Götz, H.; Shamier, M.C.; van Leeuwen, L.P.; Schmitz, K.S.; Alblas, K. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat. Med. 2023, 29, 270–278. [Google Scholar] [CrossRef]
- Van Ewijk, C.E.; Miura, F.; Rijckevorsel, G.; de Vries, H.J.; Welkers, M.R.; van den Berg, O.E.; Friesema, I.H.; van den Berg, P.; Dalhuisen, T.; Wallinga, J. Monkeypox outbreak in the Netherlands in 2022: Public health response, epidemiological and clinical characteristics of the first 1000 cases and protection of the first-generation smallpox vaccine. medRxiv 2022. [Google Scholar] [CrossRef]
- Bertran, M.; Andrews, N.; Davison, C.; Dugbazah, B.; Boateng, J.; Lunt, R.; Hardstaff, J.; Green, M.; Blomquist, P.; Turner, C. Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: An observational study. Lancet Infect. Dis. 2023, 23, 828–835. [Google Scholar] [CrossRef] [PubMed]
- Agunbiade, S.; Burton, F.; Muirhead, J.; Whitlock, G.G.; Girometti, N. Clinical characteristics of mpox infection in individuals who received a first dose of modified vaccinia Ankara immunisation. Sex. Transm. Infect. 2023, 99, 198–199. [Google Scholar] [CrossRef] [PubMed]
- Merad, Y.; Gaymard, A.; Cotte, L.; Perpoint, T.; Alfaiate, D.; Godinot, M.; Becker, A.; Cannesson, O.; Batalla, A.-S.; Oria-Yassir, F. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): A retrospective observational study in Lyon, France, June to August 2022. Eurosurveillance 2022, 27, 2200882. [Google Scholar] [CrossRef] [PubMed]
- Hubert, M.; Guivel-Benhassine, F.; Bruel, T.; Porrot, F.; Planas, D.; Vanhomwegen, J.; Wiedemann, A.; Burrel, S.; Marot, S.; Palich, R. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. Cell Host Microbe 2023, 31, 937–948.e4. [Google Scholar] [CrossRef]
- Whitehouse, E.R.; Bonwitt, J.; Hughes, C.M.; Lushima, R.S.; Likafi, T.; Nguete, B.; Kabamba, J.; Monroe, B.; Doty, J.B.; Nakazawa, Y. Clinical and epidemiological findings from enhanced monkeypox surveillance in Tshuapa province, Democratic Republic of the Congo during 2011–2015. J. Infect. Dis. 2021, 223, 1870–1878. [Google Scholar] [CrossRef]
- Zeng, Y.; Liu, X.; Li, Y.; Lu, J.; Wu, Q.; Dan, D.; Lv, S.; Xia, F.; Hu, C.; Li, J. The assessment on cross immunity with smallpox virus and antiviral drug sensitivity of the isolated mpox virus strain WIBP-MPXV-001 in China. Emerg. Microbes Infect. 2023, 12, 2208682. [Google Scholar] [CrossRef]
- Sammartino, J.C.; Cassaniti, I.; Ferrari, A.; Piralla, A.; Bergami, F.; Arena, F.A.; Paolucci, S.; Rovida, F.; Lilleri, D.; Percivalle, E. Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects. J. Med. Virol. 2023, 95, e28778. [Google Scholar] [CrossRef]
- Raadsen, M.P.; Dahlke, C.; Fathi, A.; Lamers, M.M.; van den Doel, P.; Zaeck, L.M.; van Royen, M.E.; de Bruin, E.; Sikkema, R.; Koopmans, M. Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. J. Infect. Dis. 2023, 228, 586–590. [Google Scholar] [CrossRef]
- Gushchin, V.A.; Ogarkova, D.A.; Dolzhikova, I.V.; Zubkova, O.V.; Grigoriev, I.V.; Pochtovyi, A.A.; Iliukhina, A.A.; Ozharovskaia, T.A.; Kuznetsova, N.A.; Kustova, D.D. Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus. Front. Immunol. 2022, 13, 1023164. [Google Scholar] [CrossRef]
- Ahmed, S.F.; Sohail, M.S.; Quadeer, A.A.; McKay, M.R. Vaccinia virus vaccination is expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus. BioRxiv 2022. [Google Scholar] [CrossRef]
- Català, A.; Clavo-Escribano, P.; Riera-Monroig, J.; Martín-Ezquerra, G.; Fernandez-Gonzalez, P.; Revelles-Peñas, L.; Simon-Gozalbo, A.; Rodríguez-Cuadrado, F.J.; Castells, V.G.; de la Torre Gomar, F.J. Monkeypox outbreak in Spain: Clinical and epidemiological findings in a prospective cross-sectional study of 185 cases. Br. J. Dermatol. 2022, 187, 765–772. [Google Scholar] [CrossRef] [PubMed]
- Flavia, C.; John, A.Z.; Sandra Ortega, F.; Minh, L.; Felix, W.; Don, J.D. Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adults. medRxiv 2022. [Google Scholar] [CrossRef]
- Cohn, H.; Cai, G.; Bloom, N.; Clark, J.; Tarke, A.; Bermúdez-González, M.C.; Altman, D.; Lugo, L.A.; Lobo, F.P.; Marquez, S. Mpox vaccine and infection-driven human immune signatures. medRxiv 2023. [Google Scholar] [CrossRef]
- Frey, S.E.; Wald, A.; Edupuganti, S.; Jackson, L.A.; Stapleton, J.T.; El Sahly, H.; El-Kamary, S.S.; Edwards, K.; Keyserling, H.; Winokur, P. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects. Vaccine 2015, 33, 5225–5234. [Google Scholar] [CrossRef] [PubMed]
- Sivapalasingan, S.; Kennedy, J.S.; Borkowsky, W.; Valentines, F.; Zhan, M.-X.; Pazoles, P.; Paolino, A.; Ennis, F.A.; Steigbigel, N.H. Immunological Memory after Exposure to Variola Virusm Monkeypox Virus, and Vaccinia Virus. J. Infect. Dis. 2007, 195, 1151–1159. [Google Scholar] [CrossRef] [PubMed]
- Hoff, N.A.; Doshi, R.H.; Colwell, B.; Kebela-Illunga, B.; Mukadi, P.; Mossoko, M.; Muyembe-Tamfum, J.-J.; Okitolonda-Wemakoy, E.; Lloyd-Smith, J.; Rimoin, A.W. Evolution of a disease surveillance system: An increase in reporting of human monkeypox disease in the Democratic Republic of the Congo, 2001–2013. Int. J. Trop. Dis. Health 2017, 25, 1–10. [Google Scholar] [CrossRef]
- Jezek, Z.; Grab, B.; Paluku, K.; Szczeniowski, M. Human monkeypox: Disease pattern, incidence and attack rates in a rural area of northern Zaire. Trop. Geogr. Med. 1988, 40, 73–83. [Google Scholar]
- Poland, G.A.; Kennedy, R.B.; Tosh, P.K. Prevention of monkeypox with vaccines: A rapid review. Lancet Infect. Dis. 2022, 22, e349–e358. [Google Scholar] [CrossRef]
- Gessain, A.; Nakoune, E.; Yazdanpanah, Y. Monkeypox. N. Engl. J. Med. 2022, 387, 1783–1793. [Google Scholar] [CrossRef]
- Engler, R.J.; Nelson, M.R.; Collins Jr, L.C.; Spooner, C.; Hemann, B.A.; Gibbs, B.T.; Atwood, J.E.; Howard, R.S.; Chang, A.S.; Cruser, D.L. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS ONE 2015, 10, e0118283. [Google Scholar] [CrossRef] [PubMed]
- Su, J.R.; McNeil, M.M.; Welsh, K.J.; Marquez, P.L.; Ng, C.; Yan, M.; Cano, M.V. Myopericarditis after vaccination, vaccine adverse event reporting system (VAERS), 1990–2018. Vaccine 2021, 39, 839–845. [Google Scholar] [CrossRef] [PubMed]
Author, Year, Country | Aim Study Design Study Setting Duration of the Study | Sample Size Population Criteria Inclusion Criteria Exclusion Criteria | Type of Intervention Vaccine Doses (Number) | Key Findings (Safety Efficacy Immunogenicity Effectiveness) |
---|---|---|---|---|
Fin, et al. 1988 [50] DRC | Studied the epidemiology of mpox in unvaccinated humans. Observational study Health institutions in the endemic regions. 1980–1984. | N = 209 Participants were categorized into: primary cases, co-primary cases, infectious cases, contact cases, household contacts, and secondary cases. | smallpox vaccine (vaccinia) | For contacts in houses and contacts outside of households, the rates of a second attack were 0.110 and 0.038, respectively. For contacts who had received vaccinations, the equivalent rates were 0.017 and 0.004, respectively. There are no appreciable variations in assault rates between younger and older unvaccinated children. Effectiveness was 85% for household contacts and 89% for further domiciliary contracts, for a total efficacy of 85%. Thus, the vaccine was offering a significant level of protection to the 70% of contacts who had a prior history of immunization. |
Whitehouse et al. 2021 Congo [62] | Enhance mpox surveillance. Observational study Congo. January 2011–December 2015 | N = 3639 Patients with confirmed mpox, irrespective of VZV status, with rash onset from January 2011 to December 2015. Median age: 14 years Males and females Different occupations | Smallpox vaccination | The incidence of confirmed case patients was nearly three-times greater in the presumed unvaccinated group than in the presumed vaccinated group, suggesting historical smallpox immunization may have some degree of cross-protection against mpox. |
Rimoin 2010 [51] DRC | Risk of human mpox infection after cessation of official smallpox vaccination campaign. Cohort Kasai Oriental province November 2005–November 2006 | N = 760 5–70 years Males: 62.1% Farmers and hunters PCR-based molecular assays were used for the diagnosis of mpox. Exclusion: 1. Cases without fever or rash 2. Cases with negative PCR | Smallpox vaccine | Inversely correlated with smallpox immunization is the risk of human mpox. The predicted vaccine effectiveness was 80.7% (95% CI: 68.2–88.4%). |
Huhn et al. 2005 [36] USA | Knowledge of the clinical manifestations of mpox. Case-control Health care settings | N = 34 6–47 years Males and females Patients with confirmed mpox | Comparison between pediatric and adult patients and between patients with and without previous smallpox vaccination | Patients under the age of 18 were more likely to be admitted to an intensive care unit. An independent association was found between nausea, vomiting, and mouth sores and a hospital stay lasting more than 48 h and 3 abnormal laboratory tests. No patients passed away, although 5 (15%) were classified as extremely unwell, and 9 (26%) spent more than 48 h in the hospital. Hospitalization or disease severity were not related to previous smallpox immunization. |
Karem et al. 2007 [37] USA | Evaluate correlations between immunological markers, smallpox vaccination status, and mpox infection outcomes. Case-control Six affected states One year following the U.S. mpox outbreak of 2003 | N = 72 <31 years and >31 years of age Males and females Cases defined by standard definition and household contacts of cases. Participants were categorized into vaccinated cases, unvaccinated cases, vaccinated contacts, and unvaccinated contacts. Exclusion: 1. unknown vaccination history 2. refused to give biological tissues | Smallpox vaccine | The smallpox vaccine does not offer full defense against systemic mpox infection. In both vaccinated and unvaccinated mpox cases, anti-OPXV IgM and CD8 responses predominated, with IgG, CD4, and memory B-cell responses indicating vaccine-derived immunity. Immune indicators showed that some vaccinated people and unvaccinated people had asymptomatic illnesses. The smallpox vaccine does not offer full defense against systemic mpox infection. In both vaccinated and unvaccinated mpox cases, anti-OPXV IgM and CD8 responses predominated, with IgG, CD4, and memory B-cell responses indicating vaccine-derived immunity. Immune indicators showed that some vaccinated people and unvaccinated people had asymptomatic illnesses. |
Catala et al. 2022 [68] Spain | To document the clinical and epidemiological characteristics of cases of mpox in the current outbreak. Cross-sectional Multiple medical facilities From 28 May–14 July 2022 | N = 185 Median age 38.7 years Males PCR-positive mpox virus-infected patients with skin/dermatological lesions | Regarding risk factors for severity, the study found no distinction in the extension or quantity of lesions between patients who had received a smallpox vaccination or not. | |
Thornhill et al. 2022 [34], multi-national study | Describe the presentation, clinical course, and outcomes of PCR–confirmed monkeypox virus infections. Observational 16 countries From April–June 2022 | N = 528 Males Confirmed infections diagnosed. | Smallpox vaccination | Overall, 9% said they had already been immunized against smallpox. |
Jezek et al. 1986 DRC [52] | Attack rate among contact. Observational Health care report From 1980 to 1984 | N = 2510 0 to 4 years 5–14 years ≥15 years Contacts to mpox-infected patients | Vaccinated individuals appeared to have an effective immunity. The attack rate among contacts without a scar from a previous vaccination (7.2%) was substantially higher than the assault rate among those who had previously received a vaccination (0.9%). | |
Wolff et al. 2023 [55] Israel | Effectiveness of a single, SCT dose of MVA-BN. Electronic health records Retrospective cohort Clalit Health Services (CHS) From 23 July 2022–22 December 2022 | N = 2054 Male HCWs Eligible for the vaccine on 31 July 2022. Dispensed HIV-PrEP at least for 1 month, or diagnosed with HIV, and also were diagnosed with one or more STIs since 1 January 2022. Exclusion: Individuals who were infected with mpox before the study period | Single dose | A single dose of subcutaneous MVA-BN in this high-risk cohort is associated with a significantly lower risk of MPXV infection. |
Hubert et al. 2023 [61] France | Levels of NAbs and MVA-Abs in previously smallpox-vaccinated individuals, mpox-infected patients, and IMVANEX or MVA-HIV vaccine recipients. Cohort Hospital Henri Mondor From 2014–2015 | Uninfected donors (n = 88) MPXV-infected (n = 48) IMVANEX recipients (n = 86) MVA-HIV recipients (n = 66) Uninfected donors: 51year s MPXV-infected: 32 years IMVANEX recipients: 54 years All males except—uninfected donors Female 53 (60%) | IMVANEX vaccine two doses MVA-HIV vaccine two doses | Up to 12 weeks following the commencement of the illness, anti-MVA NAbs were found in 94% of MPXV-infected patients, 92% of IMVANEX recipients, and 97% of MVA-HIV recipients. The smallpox-vaccinated and post-mpox individuals had the greatest anti-MVA and anti-MPXV NAb titers. |
Frey 2007 [38] USA | Safety and immunogenicity of IMVAMUNE. Partially blinded RCT Saint Louis University. From 17 May 2004–21 June 2005 | N = 90 8–32 years Male: 58 (64.4%) vaccinia-naïve Negative: HBV HCV, and HIV Exclusion: 1. Military service prior to 1989 or after January 2003 2. CVS diseased | IMVAMUNE vaccine (2 doses) Dryvax(one dese) |
|
Parrino 2007 [39] USA | Safety and immunogenicity of MVA. Randomized, placebo-controlled, double-blinded RCT National Institutes of Health (NIH) December 2002 and May 2004 | VRC 201(vaccinia-naïve): 76 VRC 203(vaccinia-immune): 75 VRC 201 18–33 years (vaccinia-naïve) VRC 203 born no later than 1979 (vaccinia-immune) VRC 201: 18–33 years, without prior vaccination with any vaccinia product VRC 203: healthy volunteers, born no later than 1979 Exclusion: contraindication to receive Dryvax, history of heart | Modified Vaccinia Ankara (MVA) vaccine Vaccinia-naïve: randomized to receive one dose of Dryvax® or a 0.5 mL IM injection of TBC-MVA or placebo Vaccinia-immune: randomized to receive 1 or 2 doses of TBC-MVA or placebo. 3–12 weeks later: all participants were scheduled to receive Dryvax® |
|
SSivapalasingan 2007 [72] USA | Cellular and humoral immunity to vaccinia virus (VV) in individuals exposed to 3 different OPXV. Cohort University of Massachusetts Medical School April 2002 and October 2005 | VV vaccination (n = 154) History of Mpox (n = 7) History of variola virus (n = 8) Poxvirus-naïve (n = 15) 18–33 years Exclusion: 1. history of variola virus infection 2. history of mpox virus infection | smallpox vaccine (vaccinia) | Six of the seven individuals exhibited IFN-ELISPOT responses, all had VV-specific LP responses, and three of the seven developed VV-specific neutralizing antibodies one year after contracting the MPXV virus. |
Seaman 2010 [40] USA | To examine the effect of immunization with MVA upon challenge with replication-competent vaccinia (Dryvax). Clinical Trial From 2006–2007 | N = 36 20–34 years Males 18 (50%) Healthy men or women, at least 18 years of age, and had no history of smallpox vaccination. Exclusion: Diseased individuals or a history of smallpox vaccination | Two doses of MVA | Clinical and virologic protection against the Dryvax challenge is achieved by MVA immunization. Prior introduction of NAbs to MVA or vaccinia virus is linked to protection. ID delivered MVA induces immunologic and protective responses comparable to those induced by SC administration of a 10-fold greater dosage. By day 7, MVA patients developed NAbs titers that could be detected. The 1 × 108 subcutaneous, 1 × 107 intradermal, 1 × 107 intramuscular, and 1 × 107 subcutaneous groups all saw peaks in their responses on days 14 and 28. On day 14, the two participants in the 1 × 106 ID group’s anti-vaccinia virus NAbs responses were less intense than those in the other MVA vaccine groups, but by day 28, they were comparable. |
Wilck 2010 [41] USA | Safety and immunogenicity of MVA (ACAM3000 MVA). Clinical Trial From October 2005–March 2007 | N = 72 18–34 years Females: 43 (59.7%) Healthy men or women who were at least 18 years of age, were born after 1971 and had no history of smallpox vaccination. Exclusion: Diseased individuals or history of smallpox vaccination. | Two doses of MVA | Similar antibodies to those produced by the IM or SC methods are produced after ID immunization with MVA, but at a dose that is ten times lower. All dose levels and administration methods for MVA were well tolerated. The ID and SC routes showed more pronounced local reactogenicity than the IM route. All means of administering MVA resulted in the induction of binding antibodies to the whole virus as well as NAbs to the internal mature virion and extracellular enveloped virion forms of the vaccinia virus. These responses were stronger for the higher dose administered via each route. An interferon g enzyme-linked immunospot assay was used to determine the T-cell immunological responses to the vaccine virus, however there was no obvious correlation between the dose or delivery method. |
Kennedy, 2011 [42] USA | Compare the safety and immunogenicity of LC16m8 with Dryvax in vaccinia-naive participants. Phase I/II clinical trial Five sites inside the USA From October 2004–June 2005 | N = 154 18–34 years Males: 97 (63%) Healthy vaccinia-naive adult volunteers (year of birth, 1971–1987) with negative serology for hepatitis B and C and human immunodeficiency virus, negative urine glucose, and a normal ECG Exclusion: History of smallpox vaccination or diseased individuals | LC16m8 with Dryvax Single dose | Broad T-cell responses and Nabs antibody titers against many poxviruses, including vaccinia, mpox, and variola major, are produced by LC16m8. Local and systemic effects of the LC16m8 vaccine were similar to those that were reported after receiving Dryvax. For either vaccine, there were no clinically significant abnormalities that were indicative of cardiac damage. Antivaccinia, antivariola, and antimpox Nabs titers were obtained with both vaccines. 1:40, despite the fact that Dryvax considerably outperformed LC16m8 in terms of mean plaque reduction, neutralization titers at day 30 following vaccination for anti-NYCBH vaccinia, anti-mpox, and antivariola. Strong cellular immune responses from LC16m8 trended greater than those from Dryvax for lymphoproliferation but lower than those from IFN-c ELISPOT. |
Greenberg 2013 [43] USA | Evaluate the safety of MVA and immunogenicity in HIV-infected and uninfected subjects. phase I/II clinical trial 5 USA centers | N = 151 Male18–49 years Nonpregnant women 18–55 years vaccinia experienced or vaccinia naive previous smallpox vaccination. HIV-infected participants had to be receiving stable or no HAART for >6 months prior to enrollment. Exclusion: 1. ≥10% risk of developing myocardial infarction or coronary death within 10 years. 2. an immediate family member with the onset of IHD before age 50 years 3. a history of active AIDS, diabetes, malignancy, organ transplantation, or clinically significant and severe illness. | Two doses of MVA Vaccination | Even for those with impaired immune systems, MVA is a safe smallpox vaccine. There was just one significantly reduced total antibody titer at 2 weeks following the second vaccination, and there were no significant differences between the antibody responses of the uninfected and HIV-infected populations for NAbs. In subjects who had already been exposed to vaccinia, MVA significantly increased the antibody responses, demonstrating its potency against variola. |
Frey 2015 [71] USA | Compare the safety and immunogenicity of the standard formulation of MVA, dose, and route with both a more stable, lyophilized formulation and with an antigen-sparing intradermal ID route of administration. Phase II RCT 8 sites inside the USA From 9 February–2 September 2010. | N = 524 18–38 years Males 49.6% Healthy, born after 1971, not pregnant, and had an acceptable ECG, ≤10% risk of myocardial infarction or coronary death, and no evidence of a vaccinia scar, history of smallpox vaccination, or history of eczema. Exclusion: Unhealthy subjects | MVA Lyophilized-SC/Liquid-SC/Liquid-ID Two doses | Only after the initial vaccination did moderate/severe functional local reactions substantially differ between the Lyophilized-SC (30.3%), Liquid-SC (13.8%), and Liquid-ID (22.0%) groups. After receiving any vaccination, the Liquid-SC group (58.1%), the Lyophilized-SC group (58.2%), and the Liquid-ID group all experienced moderate-to-severe quantifiable erythema and/or induration (58.1%). 36.1% of the participants in the ID Group experienced temporary, minor skin darkening at the injection site. The geometric mean of peak NAbs titers for the Lyophilized-SC, Liquid-SC, and Liquid-ID groups, respectively, was 87.8, 49.5, and 59.5 after the second vaccination day (42–208), and the maximum proportion of responders based on peak titer in each group was 97.9%, 95.3%, and 194.5%, respectively. Only 54.3%, 39.2%, and 35.2% of individuals were still seropositive for the Lyophilized-SC, Liquid-SC, and Liquid-ID groups 180 days after the second vaccination, when geometric mean NAbs dropped to 11.7, 10.2, and 10.4, respectively. |
SFAhmed 2022 [67] Australia | Investigate the expected cross-reactive immunity of VACV against the MPXV-2022 outbreak viruses. Cohort study Databases Genes analysis (humans) 2022 | Vaccinia virus (VACV). Three major types: First-generation vaccines comprise live VACV, e.g., Dryvax Second-generation vaccines comprise live VACV, e.g., ACAM2000, 3) Third-generation vaccine, Bavarian Nordic’s MVA-BN | The genetic similarity between the VACV reference sequence and the VACV-based vaccination sequences is approximately 98%. (Dryvax, ACAM2000, and MVA-BN). These VACV-based vaccinations against MPXV-2022 were expected to generate cellular immunity similar to that shown with first-generation vaccines against MPXV-CB. There was a substantial genetic similarity between VACV and the MPXV-2022 consensus sequence and the MPXV-CB reference sequence for all eight immunogenic proteins (range: 94–98%). | |
R Arbel 2022 [54] Israel | Evaluate effectiveness after providing one dose of MVA to individuals at risk of MPVX infection. Cohort study Electronic medical records Clalit Health Services From 31 July 2022–12 September 2022 | N = 1970 18–42 years Males Dispensed HIVPrEP at least for one month, or who were diagnosed with HIV and also were diagnosed with one or more of the following STIs since 1 January 2022 (Active Syphilis, Chlamydia, or Gonorrhea) Exclusion: Participants were vaccinated after 18 August 2022, and those who were infected with MPXV before the study period. | One dose of Modified Vaccinia Ankara (MVA) | Overall, 44% received the MVA vaccine and followed up for at least 25 days. Infections with MPX occurred in 15 subjects who were unvaccinated (40.0 per 100,000 person-days) and in 3 participants who were vaccinated (6.4 per 100,000 person-days) (95% CI: 24–94%). a 79% decrease in the probability of infection in those who are susceptible to MPX infection. |
Bertran 2022 [58] UK | Assess the effectiveness of MVA–BN against laboratory-confirmed symptomatic mpox disease in the GBMSM. Observational study Primarily sexual health services 21 December 2022 | N = 363 5 years and older Males Only cases with an index date from 4 July–9 October 2022 Exclusion: Females, self-reported heterosexual men, and those with missing vaccination information. | A single dose of Modified Vaccinia Ankara–Bavaria Nordic (MVA–BN) | A single MVA–BN dose was highly protective against symptomatic mpox disease among at-risk GBMSM. |
Duffy 2022 [44] USA | To detect adverse events after vaccination Cross-sectional survey Datalink health surveillance systems From 22 May–21 October 2022 | N = 1350 All ages Males and females Vaccine recipients of all ages | JYNNEOS 0.1 mL doses by ID injection for adults aged ≥18 years SC 0.5 mL doses for persons aged <18 years | During the 2022 mpox outbreak, monitoring of the JYNNEOS vaccine’s safety in the US has not revealed any fresh or unanticipated safety issues among adults. |
Farrar 2022 [45] USA | Describe the Demographic and Clinical Characteristics of Mpox of cases occurring ≥14 days after receipt of 1 dose of JYNNEOS vaccine and compared to unvaccinated persons. Cross-sectional survey 29 U.S. Jurisdictions From 22 May–3 September 2022 | N = 6606 ≥18 years Males and females 276 mpox cases who received 1 dose of JYNNEOS vaccine ≥14 days before illness onset and 6329 unvaccinated. Exclusion: No available vaccination information | A single dose of the JYNNEOS Vaccine | People who contract mpox after receiving a dose of the JYNNEOS vaccine may experience less severe symptoms. Compared to mpox individuals who were unvaccinated, several symptoms were observed less frequently. Hospitalization rates for vaccinated individuals were lower than those for unvaccinated patients (8%) at 2%, and systemic symptoms like fever and chills were less common among vaccinated patients. |
VAGushchin 2022 [66] Russia | To study residual immunity, Serum samples were examined for the presence of IgG antibodies against the Vaccinia virus, as well as for the ability to neutralize plaque formation with the Vaccinia virus MNIIVP-10 strain. Cross-sectional study Moscow From 2–16 June 2022 | N = 2908 30–80 years Males and females People living in the city of Moscow. Exclusion: No age information | Vaccinia administration | A titer of 1/20 or higher is detected in 33.3–53.2% of those over the age of 45. The percentage of people having viral NAbs among 30- to 45-year-olds who are likely unvaccinated ranged from 3.2–6.7%. Despite having higher levels of antibodies, those beyond the age of 66 had a somewhat lower percentage of positive samples than those between the ages of 46 and 65.A titer of 1/20 or higher is detected in 33.3–53.2% of those over the age of 45. The percentage of people having viral NAbs among 30- to 45-year-olds who are likely unvaccinated ranged from 3.2–6.7%. Despite having higher levels of antibodies, those beyond the age of 66 had a somewhat lower percentage of positive samples than those between the ages of 46 and 65. |
Hazra 2022 [66] USA | To describe mpox infections after a single dose of MVA-BN. Cohort study Electronic medical record From 28 June–9 September 2022 | N = 90 All ages Males and females Patients who tested positive for mpox at least 1 day after receiving the first dose of the MVA-BN Exclusion: Not vaccinated or no vaccination status | A single dose of MVA-BN, JYNNEOS | The bulk of post-vaccination mpox infections happened within two weeks of receiving the first dose of MVA-BN before complete efficacy was probably attained. |
Merad 2022 Lyon, [60] France | Determine the outcomes of at-risk contacts of mpox cases vaccinated with a single MVA-BN dose given post-exposure. Cohort study Auvergne-Rhône-Alpes region. From 15 June–12 August 2022 | N = 108 29–44 years 97 men (90%), 11 women (10%) Vaccinated with one dose of MVA-BN (IMVANEX) as part of post-PEPV. Exclusion: Mpox symptoms documented before vaccination. Time from contact to vaccination >14 days Missing data, withdrew consent | One dose of MVA-BN ≤ 14 days post-exposure | Overall, 10% of vaccinated contacts of mpox cases did not have symptomatic mpox after receiving a single MVA-BN dose of PEPV. Notwithstanding PEPV, a symptomatic illness appears in contact with a case of mpox within 21 days of exposure. |
Payne 2022, USA [46] | Examine the JYNNEOS vaccination’s protection against mpox. Cross-sectional survey 43 USA jurisdictions From 31 July–1 October 2022 | N = 9544 18–49 years Male Unvaccinated or had received either 1 or 2 JYNNEOS doses, and reported mpox | 1st and 2nd doses of JYNNEOS vaccine | Mpox incidence estimates were higher among those who had not received vaccinations compared to those who had received only one dose of the JYNNEOS vaccine within the previous 14 days (IRR = 7.4; 95% CI = 6.0–9.1) and those who had received dose two within the previous 14 days (IRR = 9.6; 95% CI = 6.9–13.2). |
Payne 2022 [47] USA | Examine the incidence of mpox among unvaccinated persons and those who had received ≥1 JYNNEOS vaccine dose as PEP. Cross-sectional study 32 USA jurisdictions From 31 July–3 September 2022 | N = 5402 18–49 years Males Reported mpox | 1st and 2nd doses of JYNNEOS vaccine | The average mpox incidence (cases per 100,000) was 14.3 (95% CI = 5.0–41.0) times higher in unprotected individuals than it was in those who had received one dose of the JYNNEOS vaccine 14 days prior. |
LPriyamvada 2022 [53] DRC | Assess the quality and longevity of serological responses to two doses of JYNNEOS vaccine. Cohort study Kinshasa and Tshuapa Province in the DRC | N = 999 18 years or older Both sex HCWs Exclusion: Pregnant women | Two doses of JYNNEOS then, the IMVAMUNE vaccine | Participants who have received vaccinations before and those who have not produced MPXV-NAbs and vaccinia virus in response to JYNNEOS immunization. At the 2-year timepoint, the majority of subjects are still IgG seropositive. The substantial increase in antibody titers was caused by immunization (Peak at D42), but two years after the vaccination, fall to baseline levels |
VanEwijk 2022 [57] Netherlands | Public health response, epidemiological and clinical characteristics of the first 1000 cases and protection of the first-generation smallpox vaccine. Observational study From 20 May–8 August 2022. | N = 1000 31–45 years Males and females Cases were reported as confirmed, probable, and possible cases. Confirmed MPX cases were categorized into mild or more severe MPX | Vaccine effectiveness of the prior first-generation smallpox vaccine against more severe MPX of 58% (95% CI 17–78%). | |
Agunbiade 2023 [59] UK | Clinical characteristics of mpox infection in individuals after 1st dose of MVA Cohort study Health clinics part of Chelsea and Westminster Hospital NHS Foundation Trust, in London (UK) From 20 June–31 October 2022 | N = 10,068 Gay, bisexual, and other men who have sex with men (GBM) Confirmed infection by RT-PCR and received a single dose of (MVA-BN) at least 1day prior to the onset of mpox-associated symptoms | Single dose MV | Of the 10,068 individuals who received the first dose of the MVA-BN vaccination, 15 (0.15%) developed mpox subsequently. All individuals identified were GBM with 12/15 (80%) on PrEP and 3/15 (20%) PLWH. |
Cohn 2023 USA [70] | Examine the polyclonal serum and single B cell antibody repertoires and T cells induced by the JYNNEOS vaccine as well as mpox infection. Cross-sectional | N = 16 (10 vaccinated with JYNNEOS, 6 infected) Vaccinated: males Infected: males (83.3%) and females Vaccinated: 21–30 years (10%), 31–40 years (40%), 41–50 years (50%) Infected: 31–40 years (50%), 41–50 years (33.3%), 51–60 years (33.3%) | 1 dose and 2 doses of JYNNEOS vaccine | Gene-level plasmablast and antibody responses were negligible and JYNNEOS vaccinee sera displayed minimal binding to recombinant mpox proteins and native proteins JYNNEOS vaccine recipients presented comparable CD4 and CD8 T cell responses against orthopox peptides to those observed after mpox infection JYNNEOS immunization does not elicit a robust B cell response. Recent mpox infection: (within 20–102 days) induced robust serum antibody responses to A29L, A35R, A33R, B18R, and A30L, and to native mpox proteins compared to the vaccine. |
Deputy 2023 [48] USA | Assess the effectiveness of JYNNEOS vaccination in preventing medically attended mpox disease among adults. Case-control Epic Cosmos platform, electronic health record (EHR) database From 15 August–19 November 2022 | N = 10,915 (2266 case, 8649 control) All ages Males, females, and other Cases: with initial mpox diagnosis or a positive mpox laboratory test. Control patients: with HIV diagnosis or a positive HIV test, or a new or refill order for HIV PrEP Exclusion: Patients with a previous mpox diagnosis or positive MPXV laboratory test | 1 dose (partial vaccination) or 2 doses (total vaccination) of the JYNNEOS vaccine | Single-dose effectiveness was 35.8% (95% CI, 22.1 to 47.1), while two-dose effectiveness was 66.0% (95% confidence interval [CI], 47.4 to 78.1) |
Ilchmann 2023 [35] Europe | To assess safety, immunogenicity, and boost response with MVA-BN in healthy adults with and without prior smallpox vaccination. The initial study: phase 2, partially randomized, double-blind, placebo-controlled, noninferiority trial. The follow-up study: 2 open-label trial A single European site 3 years (2006–2009) | The initial study N = 745 Participants naive to smallpox vaccination were randomized to: 1 dose MVA-BN (n = 181) 2 doses MVA-BN (n = 183) placebo (n = 181). Participants with previous smallpox vaccination received 1 MVA-BN booster (HSPX, n = 200). The follow-up study N = 152 1 dose MVA-BD (n = 77) 2 doses MVA-BD (n = 75) 18–55 years Male and females non-pregnant women No comorbidity | Participants without prior smallpox vaccination were randomized 1:1:1 to receive vaccinations 4 weeks apart with 1 dose of MVA-BN followed by 1 dose of placebo (1 × MVA), 2 doses of MVA-BN (2 × MVA), or 2 doses of Tris buffer placebo (PBO). Participants with prior smallpox vaccination were given a single booster dose of MVA-BN. The follow-up study: participants without prior smallpox vaccination (1 × MVA BD and 2 × MVA BD groups) Participants with previous smallpox vaccination received 1 MVA-BN booster | NAbs geometric mean titers increased after vaccination among naïve and among those who received a prior smallpox vaccination. |
Raadsen 2023 [65] Germany | Report that cross-reactive mpox virus NAbs. A single-center, open-label phase 1 clinical trial 2017 and 2018 | N = 10 18–40 years Participants without previous VACV | MVA Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein 1st, 2nd and 3rd dose | Cross-reactive mpox virus NAbs were detectable in only one participant after the first dose of the MVA-MERS-S vaccine, in 3 of 10 after the 2nd dose, and in 10 of 10 after the third dose. |
Sammartino 2023 [64] Italy | Evaluation of humoral response elicited by natural infection and healthy vaccinated subjects, including historically smallpox-vaccinated individuals and newly vaccinated subjects. Cohort study May and August 2022 | N = 123 20–71 years Males and females Individuals diagnosed with MPXV infection including HCWs | Vaccinated with VACV 1st and 2nd dose. | A robust immune response brought on by the natural infection can stop the condition. A second dose increases the serological response in naive subjects to levels that are comparable to those of MPXV patients. The t-cellular response is the most obvious sign of protection in smallpox-vaccinated controls even years after vaccination. |
KASharff 2023 [49] USA | Evaluate cardiac AESI following JYNNEOS vaccination; describe the incidence of cardiac AESIs in the Kaiser Permanente Northwest (KPNW) population who received a JYNNEOS vaccination. Cohort study Electronic health records From 14 July–10 October 2022 | N = 2126 12 years and older Males and females The patients were vaccinated with at least 1 dose of the JYNNEOS vaccine, had been a KPNW member at the time of vaccination, and through the 21-day follow-up period | JYNNEOS vaccination | Overall, 10 cardiac AESIs were found, with a frequency of 3.1 per 1000 doses out of 3236 doses. Immunization against smallpox may provide cross-protection to the mpox 8.5% had detectable antibodies. The group of people 71 to 80 years old had the highest coverage (78%) rate. A priority should be given to their vaccination because 31.5% of this demographic have low antibody levels. |
Overton 2023 [26] USA | Show the consistency of Nabs immune responses to 3 consecutively produced lots of FD MVA-BN. To assess uncommon adverse reactions, with a focus on cardiac signs and symptoms indicating myo-/pericarditis. RCT double-blind, multicenter, phase 3 trial 12 sites in the United States 2020 | N = 1129 Group 1 (n = 377) Group 2 (n = 375) Group 3 (n = 37) 18–45 years Males and females Healthy non-pregnant and non-lactating women | Vaccine-freeze-dried formulation of MVA-BN 2 vaccinations doses 4 weeks apart. | Overall, 91.2% of participants reported encountering locally solicited AEs. For 87.2% and 73.2% of all individuals, respectively, injection site discomfort and injection site erythema were the most frequently reported local requested adverse events (AEs). During the entire immunization period, 69.6% of all individuals reported experiencing general solicited adverse events. Myalgia, weariness, and headache were the most typical general requested AEs, affecting 40.6–45.5% of all patients. Nine subjects (0.8%) throughout the three lots reported a total of nine serious adverse events (SAEs). Six subjects reported a total of eight cardiac-related adverse events of special interest (AESIs) throughout the entire immunization period (0.5% across the three lots). Nabs antibody GMTs had risen from undetectable two weeks after the second vaccination (at Week 6), to 252.7 for Lot Group 1, 269.9 for Lot Group 2, and 242.0 for Lot Group 3. There were no statistically significant differences between the three lot groups for neutralizing and total antibodies; however, seroconversion rates 2 weeks after the second vaccination were above 98.0% for both Nabs and total antibodies in all groups. |
Zaeck 2023 [56] Netherlands | Measured MVA-reactive, VACV-reactive, and MPXV-reactive binding and neutralizing antibodies in cohorts of historic smallpox-vaccinated, MPXV PCR-positive, MVA-BN-vaccinated and MVA-H5-vaccinated individuals. Cohort study 2022 | N = 238 participants sera collected in 2022 (n = 126) (n = 59 born before or during 1974 (n = 59) born after 1974 (n = 67) Healthy individuals and patients suspected of having MPXV infection | After both an MPXV infection and a previous smallpox vaccine, MPXV-Nabs can be found. In non-primed people, a two-shot MVA-BN immunization series results in comparatively modest levels of MPXV-neutralizing antibodies. Lower MPXV-Nabs levels result from dose-sparing an MVA-based influenza vaccine, but a third dose of the same MVA-based vaccine considerably increases the antibody response. | |
Zeng 2023 [63] China | Evaluated the Nabs level in serum samples from participants based on year of birth. Lab study using vesicle swabs of a mpox-infectious case. Hong Kong | N = 30 Individuals who were immunized (n = 15) born ≤1981 Non-immunized with smallpox vaccine (n = 15) born >1981 | Only 26.7% of sera obtained from people born between 1981 and today tested positive using the MPXV IgG Elisa kit, which is consistent with MPXV Nabs. Sera that were unable to Nabs MPXV tested negative in the ELISA for MPXV IgG antibodies. | |
Falvi, 2022 [69] USA | Demonstrate that vaccinations of COH04S1 can elicit robust OPXV immunity. Open-label and randomized, placebo-controlled, phase 1 City of Hope (COH) as part of a clinical protocol 6 months | 20, Male 8 (40%), 36y (22, 54) Inclusion: Healthy adult Exclusion: Age < 18 or >55, previous SARS-CoV-2 infection, and poxvirus vaccination | two doses of COH04S1 at days 0 and 28 low-dose (DL1, 1 × 107 pfu), medium-dose (DL2, 1 × 108 pfu), or high-dose (DL3, 2.5 × 108 pfu) of vaccine | Regardless of the dose, COH04S1 demonstrated post-vaccination increases in MVA-specific IgG, NAb titers, and significant OPXV-specific cellular responses that persisted for more than six months. Over the course of five months following the second vaccination, MVA-specific NAb and IgG titers decreased, although they remained above baseline. A seroconversion rate of 30–60% was observed in DL1 cohorts. DL2 and DL3 patients displayed 100% seroconversion following the initial dosage. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ghazy, R.M.; Elrewany, E.; Gebreal, A.; ElMakhzangy, R.; Fadl, N.; Elbanna, E.H.; Tolba, M.M.; Hammad, E.M.; Youssef, N.; Abosheaishaa, H.; et al. Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine. Vaccines 2023, 11, 1708. https://doi.org/10.3390/vaccines11111708
Ghazy RM, Elrewany E, Gebreal A, ElMakhzangy R, Fadl N, Elbanna EH, Tolba MM, Hammad EM, Youssef N, Abosheaishaa H, et al. Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine. Vaccines. 2023; 11(11):1708. https://doi.org/10.3390/vaccines11111708
Chicago/Turabian StyleGhazy, Ramy Mohamed, Ehab Elrewany, Assem Gebreal, Rony ElMakhzangy, Noha Fadl, Eman Hassan Elbanna, Mahmoud M. Tolba, Elsayed Mohamed Hammad, Naglaa Youssef, Hazem Abosheaishaa, and et al. 2023. "Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine" Vaccines 11, no. 11: 1708. https://doi.org/10.3390/vaccines11111708